Opendata, web and dolomites

AlternativesToGd SIGNED

Hyperpolarised MR technologies and molecular probes as alternatives for conventional metal-containing contrast agents for MRI examinations

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AlternativesToGd project word cloud

Explore the words cloud of the AlternativesToGd project. It provides you a very rough idea of what is the project "AlternativesToGd" about.

bodies    alternativestogd    sufficiently    mri    ing    sends    patients    gbca    brain    message    doses    models    sensitivity    innovative    individuals    nuclear    warning    shift    disease    ema    safe    injection    unobtained    food    completely    hp    gd    detection    undergoing    accumulation    agents    metal    contrast    clinical    ca    imaging    tumour    resonance    arises    diagnostic    medicines    recently    rapid    society    mr    clear    endogenous    scientific    hyperpolarised    ones    absence    small    diagnosis    eliminated    vision    human    health    decision    scan    gbcas    paradigm    outcomes    beneficial    compounds    bearing    containing    spins    free    community    molecules    validate    magnetic    technologies    fda    labels    suspension    recommended    species    animal    class    lifetimes    body    administration    tested    techniques    diseases    radically    decay    hyperpolarisation    cas    showing    seek    carefully    gadolinium    drug    organs    risk    consist    alternatives    exam    enhanced    agency    characterisation    relates    made   

Project "AlternativesToGd" data sheet

The following table provides information about the project.

Coordinator
HADASSAH MEDICAL ORGANIZATION 

Organization address
address: N/A
city: JERUSALEM
postcode: 91120
website: www.hadassah.org.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙065˙956 €
 EC max contribution 3˙065˙956 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-2018-2019-2020-01
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2022-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HADASSAH MEDICAL ORGANIZATION IL (JERUSALEM) coordinator 346˙250.00
2    RS2D FR (MUNDOLSHEIM) participant 450˙750.00
3    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 339˙985.00
4    DANMARKS TEKNISKE UNIVERSITET DK (KGS LYNGBY) participant 339˙975.00
5    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 332˙226.00
6    MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV DE (MUENCHEN) participant 326˙250.00
7    EIBIR GEMEINNUTZIGE GMBH ZUR FORDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG AT (WIEN) participant 300˙625.00
8    UNIVERSITA DEGLI STUDI DI TORINO IT (TORINO) participant 270˙000.00
9    FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA IT (GENOVA) participant 180˙207.00
10    UNIVERSITAET ULM DE (ULM) participant 179˙687.00

Map

 Project objective

Recently, the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA) recommended suspension and warning labels for Gadolinium (Gd)-bearing CAs (GBCA) used in magnetic resonance imaging (MRI). This decision, although made in the absence of any clinical evidence, relates to potential major health concerns resulting from long-term accumulation of Gd containing species in patients’ bodies. This sends a clear message that we need to carefully consider the necessity of each contrast injection in individuals undergoing an MRI scan. However, for a number of diagnostic procedures, such as tumour characterisation, the use of a CA is often essential. The accumulation of Gd in different organs (including the brain) and GBCA-related diseases requires the scientific community to seek radically new alternatives. The AlternativesToGd vision is to identify and validate radically new compounds and technologies as alternatives to GBCAs. The new compounds and technologies developed in this proposal will be tested in animal models of disease and the most promising ones selected for further clinical development. The expected outcomes should radically impact the field, likely leading to a paradigm shift in MR-based diagnosis and thus being highly beneficial to society. The AlternativesToGd consortium will develop a new class of MRI CAs that will be metal-free, safe, and completely eliminated from the human body after the MRI exam. The agents will consist of small endogenous molecules, in which nuclear spins will be hyperpolarised to ensure high sensitivity to MR detection, even at very low doses. A major challenge and risk arises from the rapid decay of the hyperpolarised (HP) state. As enabling technologies, AlternativesToGd focuses on three leading and innovative hyperpolarisation techniques and on unique agents showing HP state lifetimes that are sufficiently long to enable diagnostic contrast-enhanced MRI approaches with so far unobtained sensitivity.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ALTERNATIVESTOGD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ALTERNATIVESTOGD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

BioProMarL (2019)

Bio-inspired Protection of Marble with Lasers

Read More  

QUEFORMAL (2019)

Quantum Engineering for Machine Learning

Read More  

PANACHE (2020)

Production of next generation modulators of pannexins and connexins as novel therapeutics in the treatment of inflammatory cardiovascular, hepatic and joint diseases.

Read More